Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function
主要な著者: | Chapman, K, Pavord, I, Paggiaro, P, Sciurba, F, Bafadhel, M, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S |
---|---|
フォーマット: | Conference item |
出版事項: |
American Thoracic Society
2018
|
類似資料
-
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
著者:: Bafadhel, M, 等
出版事項: (2018) -
Mepolizumab for eosinophilic COPD
著者:: Sciurba, F, 等
出版事項: (2018) -
Mepolizumab for eosinophilic chronic obstructive pulmonary disease
著者:: Pavord, I, 等
出版事項: (2017) -
Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
著者:: Pavord, I, 等
出版事項: (2017) -
Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
著者:: Gunsoy, N, 等
出版事項: (2017)